2 recruiting, 1 completed, 1 not yet recruiting, 1 temporarily not available. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Rapa Therapeutics LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| RAPA-501 Therapy for ALS RAPA-501 Autologous T stem cells - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Recruiting | Rapa Therapeutics LLC | 41 | 2025-01-02 | 2026-09-29 |
| RAPA-201 Therapy of Solid Tumors RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody) - Solid Tumor, Small Cell and Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Rapa Therapeutics LLC | 37 | 2021-08-01 | 2025-05-14 |
| RAPA-501-Allo Therapy of COVID-19-ARDS RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo - Severe COVID-19 Disease | Phase 1 / Phase 2 | Terminated | Rapa Therapeutics LLC | 1 | 2020-12-30 | 2021-11-11 |
| RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma RAPA-201 Autologous T cells - Relapsed, Refractory Multiple Myeloma | Phase 2 | Completed | Rapa Therapeutics LLC | 15 | 2020-12-02 | 2025-05-15 |
| RAPA-501 Therapy of ALS Expanded Access Protocol RAPA-501 Autologous T stem cells - Amyotrophic Lateral Sclerosis | Temporarily not available | Rapa Therapeutics LLC | 2026-02-12 |
Amyotrophic Lateral Sclerosis (2) · Melanoma (2) · Rare Diseases (2) · Acute Lung Injury (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Lung Injury (1) · Multiple Myeloma (1) · Pneumonia (1) · Recurrence (1)
pembrolizumab (1)
United States (6)
Daniel Fowler, M.D. (5) · Daniel H Fowler, M.D. (1)
U01NS136020 (1)